serw-MX  [xml]  
 


    
 DeCS Categories

C10 Nervous System Diseases .
C10.228 Central Nervous System Diseases .
C10.228.662 Movement Disorders .
D01 Inorganic Chemicals .
D01.146 Calcium Compounds .
D01.146.275 Calcium Carbonate .
D01.200 Carbon Compounds, Inorganic .
D01.200.275 Carbonic Acid .
D01.200.275.150 Carbonates .
D01.200.275.150.150 Calcium Carbonate .
D01.578 Minerals .
D01.578.200 Calcium Carbonate .
D02 Organic Chemicals .
D02.455 Hydrocarbons .
D02.455.426 Hydrocarbons, Cyclic .
D02.455.426.559 Hydrocarbons, Aromatic .
D02.455.426.559.389 Benzene Derivatives .
D02.455.426.559.389.097 Benzenesulfonates .
D02.455.426.559.389.097.250 Ethamsylate .
D02.845 Semicarbazides .
D02.845.746 Semicarbazones .
D02.845.746.703 Thiosemicarbazones .
D02.845.746.703.450 Methisazone .
D02.886 Sulfur Compounds .
D02.886.645 Sulfur Acids .
D02.886.645.600 Sulfonic Acids .
D02.886.645.600.080 Arylsulfonic Acids .
D02.886.645.600.080.050 Arylsulfonates .
D02.886.645.600.080.050.100 Benzenesulfonates .
D02.886.645.600.080.050.100.300 Ethamsylate .
D02.886.803 Thiosemicarbazones .
D02.886.803.450 Methisazone .
D03 Heterocyclic Compounds .
D03.066 Acids, Heterocyclic .
D03.066.515 Nicotinic Acids .
D03.066.515.400 Etazolate .
D03.383 Heterocyclic Compounds, 1-Ring .
D03.383.725 Pyridines .
D03.383.725.547 Nicotinic Acids .
D03.383.725.547.400 Etazolate .
D03.383.742 Pyrimidines .
D03.383.742.698 Pyrimidinones .
D03.383.742.698.253 Barbiturates .
D03.383.742.698.253.593 Pentobarbital .
D03.633 Heterocyclic Compounds, Fused-Ring .
D03.633.100 Heterocyclic Compounds, 2-Ring .
D03.633.100.473 Indoles .
D03.633.100.473.615 Methisazone .
D09 Carbohydrates .
D09.698 Polysaccharides .
D09.698.373 Glycosaminoglycans .
D09.698.373.475 Hyaluronic Acid .
D12 Amino Acids, Peptides, and Proteins .
D12.776 Proteins .
D12.776.124 Blood Proteins .
D12.776.124.486 Immunoproteins .
D12.776.124.486.485 Immunoglobulins .
D12.776.124.486.485.114 Antibodies .
D12.776.124.486.485.114.619 Immunoglobulin Isotypes .
D12.776.124.486.485.114.619.393 Immunoglobulin G .
D12.776.124.486.485.114.619.393.261 Etanercept .
D12.776.124.790 Serum Globulins .
D12.776.124.790.651 Immunoglobulins .
D12.776.124.790.651.114 Antibodies .
D12.776.124.790.651.114.619 Immunoglobulin Isotypes .
D12.776.124.790.651.114.619.393 Immunoglobulin G .
D12.776.124.790.651.114.619.393.261 Etanercept .
D12.776.377 Globulins .
D12.776.377.715 Serum Globulins .
D12.776.377.715.548 Immunoglobulins .
D12.776.377.715.548.114 Antibodies .
D12.776.377.715.548.114.619 Immunoglobulin Isotypes .
D12.776.377.715.548.114.619.393 Immunoglobulin G .
D12.776.377.715.548.114.619.393.261 Etanercept .
D12.776.543 Membrane Proteins .
D12.776.543.750 Receptors, Cell Surface .
D12.776.543.750.705 Receptors, Immunologic .
D12.776.543.750.705.852 Receptors, Cytokine .
D12.776.543.750.705.852.760 Receptors, Tumor Necrosis Factor .
D12.776.543.750.705.852.760.232 Etanercept .
G02 Chemical Phenomena .
G02.111 Biochemical Phenomena .
G02.111.570 Molecular Structure .
G02.111.570.080 Base Sequence .
G02.111.570.080.534 Matrix Attachment Regions .
G05 Genetic Phenomena .
G05.360 Genetic Structures .
G05.360.080 Base Sequence .
G05.360.080.534 Matrix Attachment Regions .
N04 Health Services Administration .
N04.452 Organization and Administration .
N04.452.871 Risk Management .
N04.452.871.758 Risk Evaluation and Mitigation .
N06 Environment and Public Health .
N06.850 Public Health .
N06.850.505 Epidemiologic Measurements .
N06.850.505.715 Risk Assessment .
N06.850.505.715.750 Risk Evaluation and Mitigation .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Movement Disorders .
Movement Disorder Syndromes .
Dyskinesia Syndrome .
Movement Disorder .
Movement Disorder Syndrome .
Etat Marbre .
Status Marmoratus .
Dyskinesia Syndromes .
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. .
1.00
17113597
 
Risk Evaluation and Mitigation .
ETASU .
Elements to Assure Safe Use .
Strategies required by the US Food and Drug Administration (FDA) Amendments Act of 2007 when a question exists as to whether the benefits of a drug outweigh its risks. These constitute a safety plan with several potential components, including a medication guide, a communication plan, elements to ensure safe use and an implementation system to help guide the prescribers, pharmacists and patients. .
0.53
20
 
Pentobarbital .
Diabutal .
Etaminal .
Ethaminal .
Nembutal .
Pentobarbital Sodium .
Pentobarbital, Monosodium Salt .
Pentobarbitone .
Sagatal .
Monosodium Salt Pentobarbital .
Mebubarbital .
Mebumal .
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) .
0.49
779050
 
Etanercept .
Enbrel .
Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein .
TNF Receptor Type II-IgG Fusion Protein .
TNFR-Fc Fusion Protein .
TNR 001 .
TNR-001 .
TNT Receptor Fusion Protein .
TNTR-Fc .
001, TNR .
Fusion Protein, TNFR-Fc .
Protein, TNFR-Fc Fusion .
Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein .
TNF Receptor Type II IgG Fusion Protein .
TNFR Fc Fusion Protein .
TNR001 .
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. .
0.44
 
Calcium Carbonate .
Aragonite .
Calcite .
Chalk .
Limestone .
Marble .
Milk of Calcium .
Vaterite .
Calcium Milk .
Carbonate, Calcium .
Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement. .
0.44
836213
 
Hyaluronic Acid .
Amo Vitrax .
Amvisc .
Biolon .
Etamucine .
Healon .
Hyaluronan .
Hyaluronate Sodium .
Hyvisc .
Luronit .
Sodium Hyaluronate .
Acid, Hyaluronic .
Hyaluronate, Sodium .
Vitrax, Amo .
A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA. .
0.44
17117806
 
Etazolate .
Etazolate Hydrochloride .
SQ-20009 .
Hydrochloride, Etazolate .
SQ 20009 .
SQ20009 .
A potent phosphodiesterase inhibitor proposed as an antipsychotic agent. .
0.43
069
 
Methisazone .
Marboran .
Metisazone .
An antiviral agent effective against pox viruses. .
0.42
068
 
Ethamsylate .
Altodor .
Dicinone .
Dicynene .
Dicynone .
Etamsylate .
Hemo 141 .
Cyclonamine .
Benzenesulfonate derivative used as a systemic hemostatic. .
0.41
1179
 
Matrix Attachment Regions .
MAR Elements .
MAR-SAR Recognition Signature Sequence .
Matrix-Attached Regions .
SAR Elements .
Scaffold-Attached Regions .
Element, MAR .
Element, SAR .
Elements, MAR .
Elements, SAR .
MAR Element .
MAR SAR Recognition Signature Sequence .
MRS Sequences .
Matrix Attached Regions .
Matrix Attachment Region .
Matrix-Attached Region .
Region, Matrix Attachment .
Region, Matrix-Attached .
Region, Scaffold Attachment .
Region, Scaffold-Attached .
Regions, Matrix Attachment .
Regions, Matrix-Attached .
Regions, Scaffold Attachment .
Regions, Scaffold-Attached .
SAR Element .
Scaffold Attached Regions .
Scaffold Attachment Region .
Scaffold-Attached Region .
Sequences, MRS .
MRS Sequence .
Scaffold Attachment Regions .
MAR/SAR Recognition Signature Sequence .
Regions of the CHROMATIN or DNA that bind to the NUCLEAR MATRIX. They are found in INTERGENIC DNA, especially flanking the 5' ends of genes or clusters of genes. Many of the regions that have been isolated contain a bipartite sequence motif called the MAR/SAR recognition signature sequence that binds to MATRIX ATTACHMENT REGION BINDING PROTEINS. .
0.40
1217